TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company
Transcenta, biologics, antibody
While striving to build its own R&D strength, Transcenta has established and continues to explore collaborations with renowned biotech/pharmaceutical companies and research institutions worldwide.
For Collaboration Enquires:
Eli Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions. Alebund was founded in Shanghai in early 2018, as a startup jointly incubated by a group of industry leaders in the field of nephrology and Lilly Asia Ventures. Supported by numerous renowned institutional investors specialized in the biopharmaceutical industry, Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of renal diseases, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease (ADPKD). Alehund’s pipeline comprises both small-molecule and biologic assets.
Merck , a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of € 16.2 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
IQVIA is an American multinational company serving the combined industries of health information technologies and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services. It committed to providing solutions that enable life sciences companies to innovate with confidence, maximize opportunities, and, ultimately, drive human health outcomes forward.
908 Devices is setting off a revolution in how chemical analysis gets done. We offer point-of-need chemical and biomolecular analysis devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices. These purpose-built and user-centric devices serve the life science, field forensics and other applied markets. 908 Devices is headquartered in the heart of Boston where we research, design and manufacture innovative products based on high-pressure mass spectrometryTM (HPMS) and microfluidic separation technology.
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. Mayo Clinic mission is to inspire hope and contribute to health and well-being by providing the best care to every patient through integrated clinical practice, education and research.
Harvard University is devoted to excellence in teaching, learning, and research, and to developing leaders in many disciplines who make a difference globally. The University, which is based in Cambridge and Boston, Massachusetts, has an enrollment of over 20,000 degree candidates, including undergraduate, graduate, and professional students. Harvard has more than 360,000 alumni around the world.
Inhibrx’s mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, Inhibrx has built a large and diverse pipeline with the potential to impact cancer, infectious disease and orphan diseases.
Hengrui Medicine is a leading pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Hengrui was established in 1970 and listed in Shanghai Stock Exchange in 2000. The company ranks top 30 worldwide by a market capitalization of over 30 billion USD and is home to more than 21,000 employees worldwide. Hengrui not only stands out as a front-runner in cancer drugs, contrast agents, cancer drugs, and surgical medicines, but is also a lead member of the National Anti-Tumor Medicine Technology Innovation Industry-Education-Research Alliance. Hengrui owns a National Targeted Drug Engineering Technology Research Center, and a post-doctoral research station. In May 2018, Hengrui Medicine was listed in Forbes’s top 100 world’s most innovative companies and ranked the 64th, where only 7 companies from China were on the list.
Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties.
Yale Since its founding in 1701,has been dedicated to expanding and sharing knowledge, inspiring innovation, and preserving cultural and scientific information for future generations. Yale’s reach is both local and international. It partners with its hometown of New Haven, Connecticut to strengthen the city’s community and economy. And it engages with people and institutions across the globe in the quest to promote cultural understanding, improve the human condition, delve more deeply into the secrets of the universe, and train the next generation of world leaders.
Peking University is a comprehensive and national key university. The university has effectively combined research on important scientific subjects with the training of personnel with a high level of specialized knowledge and professional skill as demanded by the country's socialist modernization. It strives not only for improvements in teaching and research work, but also for the promotion of interaction and mutual promotion among various disciplines. Peking University is proud of its outstanding faculty, including 48 members of the Chinese Academy of Sciences (CAS), 9 members of the Chinese Academy of Engineering (CAE), and 21 members of the Third World Academy of Sciences (TWAS).
Shanghai Jiao Tong University (SJTU) , as one of the higher education institutions which enjoy a long history and a world-renowned reputation in China, is a key university directly under the administration of the Ministry of Education (MOE) of the People's Republic of China and co-constructed by MOE and Shanghai Municipal Government. Through some 120 years' unremitting efforts, SJTU has become a comprehensive, research-oriented, and internationalized top university in China.
G-CON Manufacturing designs, produces and installs prefabricated, autonomous cleanroom PODs®. G-CON's cleanroom POD® portfolio encompasses a variety of different dimensions and purposes, from laboratory environments to personalized medicine and production process platforms.
Covance is a leading contract research organization (CRO) that provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Covance provide comprehensive drug development solutions and are on a mission to advance health and power clear, confident decisions.